Brief: Creative Medical Technology Announces IRB Approval For FDA Cleared Phase 1/2 Clinical Trial Of Novel Cell Therapy For The Treatment Of Type 1 Diabetes
08/02/2023 13:21
Feb 8 (Reuters) - Creative Medical Technology Holdings
Inc CELZ.O :
* CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES IRB
APPROVAL FOR
FDA CLEARED PHASE 1/2 CLINICAL TRIAL OF NOVEL CELL THERAPY FOR
THE TREATMENT OF TYPE 1 DIABETES
Source text for Eikon: ID:nPn8DKnxQa
Further company coverage: CELZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM